P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Update

P3 Health Partners Inc. (NASDAQ:PIII) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totaling 283,541 shares, an increase of 293.3% from the April 30th total of 72,094 shares. Currently, 4.8% of the company’s stock are sold short. Based on an average daily volume of 6,174,785 shares, the short-interest ratio is currently 0.0 days.

P3 Health Partners Stock Performance

Shares of PIII traded down $2.54 during trading hours on Friday, hitting $13.94. The stock had a trading volume of 57,003 shares, compared to its average volume of 819,361. The firm has a 50-day moving average price of $4.83 and a 200 day moving average price of $4.08. P3 Health Partners has a fifty-two week low of $1.52 and a fifty-two week high of $16.89. The firm has a market capitalization of $100.89 million, a price-to-earnings ratio of -0.36 and a beta of 0.48.

P3 Health Partners (NASDAQ:PIII) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($4.85) by $5.17. P3 Health Partners had a negative return on equity of 302.33% and a negative net margin of 8.57%.The firm had revenue of $386.39 million during the quarter, compared to analyst estimates of $391.45 million.

Institutional Trading of P3 Health Partners

An institutional investor recently bought a new position in P3 Health Partners stock. Lido Advisors LLC bought a new position in shares of P3 Health Partners Inc. (NASDAQ:PIII) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned about 0.15% of P3 Health Partners as of its most recent SEC filing. 7.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PIII has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of P3 Health Partners in a research report on Tuesday, April 21st. Lake Street Capital reissued a “buy” rating and set a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research report on Friday, May 15th. TD Cowen restated a “hold” rating and set a $14.00 price target (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. Finally, UBS Group set a $14.00 price target on shares of P3 Health Partners in a report on Friday, May 15th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $14.00.

About P3 Health Partners

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.